Truist Financial Corp Immuno Gen, Inc. Transaction History

Truist Financial Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 22, 2022	SELL	$4.26 - $7.48 $796,236 - $1.4 Million	-186,910 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$4.75 - $7.5 $115,106 - $181,747	-24,233 Reduced 11.48%	186,910 $1.39 Million
Q3 2021 Nov 05, 2021	BUY	$5.02 - $6.59 $878 - $1,153	175 Added 0.08%	211,143 $1.2 Million
Q2 2021 Aug 16, 2021	BUY	$5.79 - $8.6 $112,181 - $166,625	19,375 Added 10.11%	210,968 $1.39 Million
Q1 2021 May 17, 2021	SELL	$6.5 - $10.53 $185,789 - $300,978	-28,583 Reduced 12.98%	191,593 $1.55 Million
Q4 2020 Nov 19, 2021	SELL	$3.7 - $7.66 $55,688 - $115,290	-15,051 Reduced 6.4%	220,176 $1.42 Million
Q4 2020 Feb 18, 2021	BUY	$3.7 - $7.66 $164,646 - $340,862	44,499 Added 23.33%	235,227 $1.52 Million
Q3 2020 Nov 13, 2020	BUY	$3.45 - $4.89 $254,437 - $360,637	73,750 Added 63.05%	190,728 $686,000
Q2 2020 Aug 14, 2020	BUY	$3.32 - $5.34 $85,632 - $137,734	25,793 Added 28.29%	116,978 $538,000
Q1 2020 May 15, 2020	SELL	$2.12 - $6.8 $2,435 - $7,813	-1,149 Reduced 1.24%	91,185 $311,000
Q4 2019 Feb 14, 2020	BUY	$2.25 - $5.8 $207,751 - $535,537	92,334 New	92,334 $472,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Truist Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Truist Financial Corp with notifications on news.